doi: 10.1016/j.csbj.2022.09.018 107 YagodaNVon RechenbergMZaganjorEBauerAJYangWSFridmanDJet al
However, GLP-1RAs markedly reduced postprandial increases in triglycerides, apolipoprotein (Apo)B48 (major structural protein of chylomicrons), and ApoC-III (key regulator of triglyceride-rich lipoprotein metabolism), independently of gastric emptying [38,39,40]
Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Employers should stay informed about these regulatory changes to manage prescription drug costs and ensure employee medication access
Known as glucagon-like peptide-1 (GLP-1) receptor agonists, they help people lose weight by mimicking a hormone that reduces their appetite
Its crucial to discuss any potential changes in your medication with our healthcare providers